TEST:

MELAGENIX

The MELAGENIX test provides a genomic-based, comprehensive, individualized risk assessment for stage I-III melanoma patients in the adjuvant and neoadjuvant setting. The test uses quantitative RT-PCR to measure the expression of eleven genes (eight prognostic and three reference genes) in and around a tumor sample after it has been removed by surgery or biopsy. After the test, the report will provide you with a risk score between -1-4 and binarize patients into one of two risk groups. A low score means the cancer has a lower chance of returning. A high score means the cancer has a higher chance of returning.